Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis by Ma, Li et al.
Cell, Vol. 121, 179–193, April 22, 2005, Copyright ©2005 by Elsevier Inc. DOI 10.1016/j.cell.2005.02.031
Phosphorylation and Functional Inactivation of TSC2
by Erk: Implications for Tuberous Sclerosis
and Cancer Pathogenesis
Li Ma,1,2,4 Zhenbang Chen,1,2
Hediye Erdjument-Bromage,3 Paul Tempst,3,5
and Pier Paolo Pandolfi1,2,5,*
1Cancer Biology and Genetics Program
2Department of Pathology
3Molecular Biology Program
Sloan-Kettering Institute
Memorial Sloan-Kettering Cancer Center
New York, New York 10021
4Graduate Program in Physiology, Biophysics
and Systems Biology
Weill Graduate School of Medical Sciences
Cornell University
New York, New York 10021
5Weill Graduate School of Medical Sciences
Cornell University
New York, New York 10021
Summary
Tuberous sclerosis (TSC) is a tumor syndrome caused
by mutation in TSC1 or TSC2 genes. TSC tumorigene-
sis is not always accompanied by loss of heterozy-
gosity (LOH). Recently, extracellular signal-regulated
kinase (Erk) has been found activated in TSC lesions
lacking TSC1 or TSC2 LOH. Here, we show that Erk
may play a critical role in TSC progression through
posttranslational inactivation of TSC2. Erk-dependent
phosphorylation leads to TSC1-TSC2 dissociation
and markedly impairs TSC2 ability to inhibit mTOR
signaling, cell proliferation, and oncogenic trans-
formation. Importantly, expression of an Erk non-
phosphorylatable TSC2 mutant in TSC2+/− tumor cells
where Erk is constitutively activated blocks tumori-
genecity in vivo, while wild-type TSC2 is ineffective.
Our findings position the Ras/MAPK pathway up-
stream of the TSC complex and suggest that Erk may
modulate mTOR signaling and contribute to disease
progression through phosphorylation and inactiva-
tion of TSC2.
Introduction
TSC1 and TSC2 were first identified as the genes mu-
tated in patients with tuberous sclerosis (TSC), an au-
tosomal dominant disease affecting 1 out of 6000 peo-
ple. Affected individuals suffer from hamartomas in a
wide spectrum of organs (Gomez et al., 1999). TSC-asso-
ciated brain lesions, such as cortical tubers, subepen-
dymal nodules, and subependymal giant cell astrocyto-
mas (SEGAs), can result in seizures, mental retardation,
and autism (Gomez, 1988; Gomez et al., 1999).
Mutation in either TSC1 or TSC2 gene contributes
equally to this disorder (Cheadle et al., 2000). The pro-
tein products, TSC1 (or hamartin) and TSC2 (or tuberin),
physically associate in vivo and form a heterodimeric*Correspondence: p-pandolfi@ski.mskcc.orgcomplex (Plank et al., 1998; van Slegtenhorst et al.,
1998). Like other tumor suppressors, LOH of either
TSC1 or TSC2 has been reported in TSC hamartomas,
such as renal angiomyolipomas (Green et al., 1994; van
Slegtenhorst et al., 1997). However, loss of the wild-
type allele in certain types of tumors (particularly brain
lesions) is very rare (Niida et al., 2001).
TSC2 was directly linked to cell size regulation by the
discovery that mutation in dTsc2 leads to the gigas
(large cell) phenotype (Ito and Rubin, 1999). Recent
genetic studies have placed TSC2 in the phosphotidy-
linositol-3-kinase (PI3K)-target of rapamycin (TOR)
pathway, whereby the TSC1-TSC2 complex functions
downstream of Akt and upstream of TOR to restrict cell
growth and cell proliferation (Potter et al., 2001; Tapon
et al., 2001). Biochemical support to this epistatic rela-
tionship was provided when four independent groups
reported that TSC2 is a direct substrate of Akt (Dan et
al., 2002; Inoki et al., 2002; Manning et al., 2002; Potter
et al., 2002). The mechanisms by which Akt phosphory-
lation of TSC2 would lead to the functional inactivation
of the TSC1-TSC2 complex are unclear. Akt phosphory-
lation of TSC2 is nevertheless thought to result in
mTOR activation leading, in turn, to phosphorylation of
two main mTOR substrates, ribosomal p70S6 kinase
(S6K) and eukaryotic initiation factor 4E binding pro-
tein-1 (4E-BP1), and elevated mRNA translation.
Phosphorylation can also positively regulate TSC2,
as evidenced by enhanced TSC2 function in conse-
quence of TSC2 phosphorylation by AMPK, a sensor of
cellular energy status (Inoki et al., 2003b), thereby link-
ing the LKB1 tumor suppressor to the TSC complex. As
a result of energy starvation, LKB1 phosphorylates and
activates AMPK, which in turn phosphorylates and acti-
vates TSC2, leading to inactivation of mTOR as well as
the mRNA translation apparatus (Corradetti et al., 2004;
Shaw et al., 2004).
The TSC2 C-terminal region shares homology with
the catalytic domain of GTPase-activating proteins
(GAPs) and is a target of TSC-associated missense mu-
tations (Maheshwar et al., 1997; Wienecke et al., 1995).
The discovery that TSC2 is a Rheb (Ras homolog en-
riched in brain)-GAP has filled the gap between TSC1-
TSC2 and mTOR. Rheb can act as a protooncogene
and, as demonstrated by genetic analysis in Drosoph-
ila, is epistatic to dPI3k, dAkt, dTsc1, and dTsc2, while
dTOR and dS6k are epistatic to Rheb (Saucedo et al.,
2003; Stocker et al., 2003). Biochemically, TSC2 acti-
vates GTP hydrolysis by Rheb in vitro. GTP bound Rheb
is elevated in TSC2 null cells and is reduced by TSC1-
TSC2 add-back (Garami et al., 2003; Inoki et al., 2003a;
Tee et al., 2003; Zhang et al., 2003b). Moreover, coex-
pression of TSC1-TSC2 inhibits the ability of Rheb to
induce phosphorylation of S6K at T389 (Garami et al.,
2003; Inoki et al., 2003a).
S6K is a downstream target of the TSC complex. Ge-
netic studies revealed that dS6k is epistatic to dTsc1
and dTsc2 (Potter et al., 2001; Potter et al., 2002; Tapon
et al., 2001). In mammalian cells deficient in TSC1 or
TSC2, S6K is found constitutively activated, an event
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180Figure 1. TSC2 Is Phosphorylated in an Erk-Dependent Manner
(A) Phosphorylation of TSC2 upon PMA treatment and its sensitivity to U0126. 293 cells transfected with empty vector or FLAG-TSC2 were
serum-starved and then left untreated, stimulated with 1 g/ml PMA for 40 min, or pretreated with 25 M U0126 for 30 min. Lysates were
immunoprecipitated with anti-FLAG, probed with anti-pSer/Thr, and reprobed with anti-TSC2.
(B) Phosphorylation of TSC2 upon EGF treatment and its sensitivity to U0126 and wortmannin. 293 cells were transfected and serum-starved
as described in (A), and lysates were prepared from cells left untreated, stimulated with 100 ng/ml EGF for 30 min, or pretreated with 25 M
U0126 and/or 100 nM wortmannin for 30 min. Lysates were immunoprecipitated with anti-FLAG, probed with anti-pSer/Thr, and reprobed
with anti-TSC2.
(C) Phosphorylation of endogenous TSC2 upon expression of constitutively active MEK1. 293 cells transfected with empty vector or HA-
MEK1S218D/S222D were serum-starved, and lysates were immunoprecipitated with anti-TSC2 and incubated in CIP buffer with or without CIP
before being subjected to immunoblotting with anti-TSC2. To clearly demonstrate the mobility shift, optimal conditions were used (6% SDS-
PAGE and maximal separation in the 150–250 KD region).that can be reverted by TSC1-TSC2 add-back (Gon- d
gcharova et al., 2002; Kwiatkowski et al., 2002). Con-
versely, overexpression of TSC1-TSC2 represses S6K t
mactivity (Tee et al., 2002). S6K activation is regulated
through hierarchical phosphorylation: prior phosphory- A
ilation of T389 in the hydrophobic motif (H motif) by
mTOR, which most closely correlates with S6K activity c
win vivo, followed by PDK1 phosphorylation of T229 in
the activation loop (T loop; Alessi et al., 1998; Burnett t
set al., 1998; Pullen et al., 1998). Furthermore, S6K inhi-
bition by TSC1 and TSC2 is mTOR dependent (Gao et g
al., 2002; Inoki et al., 2002).
The physiological relevance of TSC2 phosphorylation c
aand inactivation by Akt is demonstrated in Drosophila,
where overexpression of an Akt nonphosphorylatable mTsc2 mutant is found to prevent Akt-induced cell
rowth (Potter et al., 2002). However, to date, the rela-
ionship between TSC2 phosphorylation by Akt and tu-
origenesis in TSC patients remains unclear. Although
kt-dependent phosphorylation of TSC2 was detected
n three TSC-associated SEGAs using a phosphospe-
ific TSC2 antibody against T1462 (Han et al., 2004),
hether TSC2 phosphorylation by Akt associated with
hese brain lesions impairs its in vivo tumor suppres-
ive function and thus plays a causal role in TSC patho-
enesis has not been determined.
Interestingly, recent clinical studies have revealed
onstitutive high levels of Erk activation in both TSC-
ssociated brain lesions that lack LOH and TSC2+/− tu-
or cell line, suggesting that Erk might play a role in
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181Figure 2. Erk Associates with TSC2 and Di-
rectly Phosphorylates TSC2 In Vitro
(A) Coimmunoprecipitation of ectopic Erk
and TSC2. 293 cells were transfected with
HA-Erk2 and/or Xpress (XP)-TSC2 and kept
in full serum. Lysates were immunoprecipi-
tated with anti-HA and blotted with TSC2
and Erk antibodies.
(B) Coimmunoprecipitation of endogenous
Erk and TSC2. Lysates harvested from 293
cells cultured in full serum were immuno-
precipitated with Erk or FAK antibody and
blotted with TSC2, Erk, and FAK antibodies,
respectively.
(C) Phosphorylation of TSC2 by Erk in vitro.
Xpress-TSC2 was immunoprecipitated by
anti-Xpress from 293T cells and incubated
with recombinant active Erk2 and [γ-32P]-
ATP. Autoradiography was performed, fol-
lowed by immunoblotting with anti-TSC2.
(D) Nonradioactive in vitro kinase assay.
FLAG-TSC2 was immunoprecipitated by
anti-FLAG from 293T cells and incubated
with recombinant active Erk2. Proteins from
this assay were blotted with anti-pSer/Thr
followed by anti-TSC2.tumor progression in TSC (Govindarajan et al., 2003;
Han et al., 2004). We therefore hypothesized that there
may be a direct relationship between MAP kinase acti-
vation and TSC2 functional inactivation in TSC tumori-
genesis. Indeed, we demonstrate here that TSC2 is a
phosphorylation target of Ras-Erk signaling and that
TSC2 direct phosphorylation by Erk results in the sup-
pression of its biochemical and biological tumor-sup-
pressive functions.
Results
Activation of MAP Kinase Signaling Results
in TSC2 Phosphorylation
The Raf-MEK1/2-Erk1/2 signaling cascade plays a key
role in the regulation of cell growth and differentiation
(Pearson et al., 2001). Activation of Erk1/2 occurs
through dual phosphorylation of threonine and tyrosine
by MAP kinase kinase (MEK1/2; Payne et al., 1991). We
observed that phorbol 12-myristate 13-acetate (PMA, a
potent cancer-promoting agent and well-known activa-
tor of the MAPK signaling pathway) markedly enhanced
TSC2 phosphorylation on serine and threonine and pre-
treatment with U0126, a MAPKK inhibitor, reduced
PMA-induced phosphorylation to basal level (Figure
1A). To date, growth factor-induced TSC2 phosphoryla-
tion is believed to occur primarily through activation of
the PI3K/Akt pathway, whereby Akt would directly
phosphorylate TSC2 at S939, T1462, and perhaps up
to five additional sites (Dan et al., 2002; Inoki et al.,
2002; Manning et al., 2002; Potter et al., 2002). How-
ever, growth factor stimulation also activates MAP ki-
nase signaling. We therefore tested the contribution of
this pathway to growth factor-induced phosphorylation
of TSC2. Either U0126 or wortmannin (a PI3K inhibitor)
could suppress TSC2 phosphorylation by EGF, while
treatment with both inhibitors led to a further reduction
(Figure 1B), suggesting that upon mitogenic stimuli,TSC2 can be phosphorylated through both MAP kinase
and PI3K/Akt pathways.
To examine whether endogenous TSC2 is phosphor-
ylated in an Erk-dependent manner, we expressed con-
stitutively active MEK1 (MEK1S218D/S222D) to activate
endogenous Erk, which led to a prominent upshift in
mobility of endogenous TSC2. Calf intestinal alkaline
phosphatase (CIP) treatment totally abolished MEK1-
induced upshift of TSC2 and confirmed that the mobil-
ity shift was the consequence of phosphorylation (Fig-
ure 1C).
Erk Directly Phosphorylates TSC2 In Vitro
The fact that blockade of MAPK pathway with MEK1/2
inhibitors leads to reduced TSC2 phosphorylation sug-
gested that either Erk itself or its kinase substrates
might directly phosphorylate TSC2, taking into account
the fact that Erk1/2 is the only known substrate of
MEK1/2. We first tested whether Erk interacted with
TSC2. TSC2 was readily coimmunoprecipitated with
overexpressed Erk (Figure 2A). Furthermore, endoge-
nous TSC2 was also coimmunoprecipitated by endoge-
nous Erk1/2, but not endogenous FAK, a kinase that is
localized to focal adhesions and does not interact with
TSC2, which is cytosol soluble (Figure 2B). Thus, Erk
and TSC2 can physically associate. In most cases, sta-
ble binding of substrates to MAP kinases involves re-
cognition of a docking site on the substrate. In general,
the Erk docking site (Erk D domain) is composed of a
conserved L/I-X-L/I motif located three to five residues
downstream of a cluster of basic amino acids (Shar-
rocks et al., 2000). TSC2 indeed contains several puta-
tive Erk D domains, e.g., KEKFKILLGLGTPRP.
Next, we determined whether Erk could directly
phosphorylate TSC2 in vitro. As shown in Figure 2C,
activated recombinant Erk2 was found to phosphory-
late TSC2 in an immunocomplex kinase assay. Phos-
phorylated TSC2 from these in vitro reactions was also
Cell
182Figure 3. Erk Phosphorylates TSC2 Predominantly on S664 In Vitro and In Vivo
(A) S664 is the primary direct Erk phosphorylation site. FLAG-TSC2 was immunoprecipitated from 293T cells and incubated with or without
active Erk2. Phosphorylation site mapping was determined by mass spectrometry. The sequence of the peptide containing phosphorylated
S664 characterized by this study is shown along with the phosphate group.
(B) Consensus Erk phosphorylation sites on human TSC2 and alignment with conserved sites on mouse and rat Tsc2. Six sites on human
TSC2 were predicted to be possible Erk phosphorylation sites by the Scansite program, among which S664 and S540 were given the highest
scores upon Scansite analysis. TSC2 modular organization is also shown along with its major domains: a leucine zipper (LZ) domain and a
coiled-coil (CC) domain at the N terminus, which are responsible for binding to TSC1; CC domain in the middle region; and a GAP domain at
the C-terminus (Li et al., 2004).
(C) S664 and S540 are required for TSC2 phosphorylation by Erk in vitro. Xpress-tagged wt TSC2 as well as S664A, S540A, and S664A/S540A
mutants were immunoprecipitated by anti-Xpress from 293T cells and used as substrates in in vitro kinase assay using recombinant active
Erk2. Autoradiography was performed, followed by immunoblotting with anti-TSC2.
(D) S664 and S540 mediate Erk-dependent phosphorylation of TSC2 in vivo. 293 cells were transfected with empty vector, HA-MEK1S218D/S222D
and/or Xpress-tagged wt TSC2 or S664A, S540A, S664A/S540A, or S939A/T1462A mutants. Lysates were prepared from cells in full serum or
in full serum with 25 M U0126 or 100 nM wortmannin for 30 min. Proteins precipitated by anti-Xpress were blotted with anti-pSer/Thr
followed by anti-TSC2.readily detected using a phosphoserine/threonine anti- d
mbody (Figure 2D). No phosphorylation was observed
without the addition of purified Erk2 (Figures 2C and p
a2D). TSC2 can therefore be a direct substrate of Erk
in vitro. o
v
fS664 Is the Primary Erk Phosphorylation Site
Pon TSC2 In Vitro and In Vivo
oTo establish the primary TSC2 phosphorylation sites,
tErk-phosphorylated and unphosphorylated TSC2 (des-
ignated as “TSC2-P” and “TSC2-C,” respectively) were sigested with trypsin and analyzed by MALDI-reTOF
ass spectrometry. Peptide patterns were then com-
ared for differences. One m/z peak, at 2060.996
tomic mass units (amu), was observed in the spectra
f “TSC2-P” that was absent from “TSC2-C.” The m/z
alue mapped to the predicted, monophosphorylated
ragment of the TSC2 sequence (TSGPLSPPTGPPGPA
AGPAVR) with monoisotopic (12C) mass discrepancies
f less than 7 ppm. Next, the same peptide was selec-
ively retrieved by affinity metal chromatography (Po-
ewitz and Tempst, 1999) and reanalyzed by MALDI-
Erk Regulates TSC2 and TSC-Related Tumorigenesis
183Figure 4. Erk Phosphorylation of TSC2 Disrupts the TSC1-TSC2 Complex
(A) Coimmunoprecipitation between TSC1 and wild-type or mutant TSC2. 293 cells were cotransfected with Myc-TSC1 and Xpress-tagged
wt TSC2, S664A/S540A (A2), or S664D/S540D (D2) mutant and kept in full serum. Lysates were immunoprecipitated with anti-Myc and blotted
with Xpress and Myc antibodies, respectively. SE: short exposure; LE: long exposure.
(B) Disruption of the ectopic TSC1-TSC2 complex upon MAPK activation. 293 cells cotransfected with Myc-TSC1 and Xpress-tagged wt
TSC2 or A2 TSC2 mutant were serum-starved, stimulated with 1 g/ml PMA for 40 min, or pretreated with 25 M U0126 for 30 min. Lysates
were immunoprecipitated with anti-Myc and blotted with Xpress and Myc antibodies, respectively.
(C) Induction of the TSC1-TSC2 association upon inhibition of basal Erk activity. 293 cells cotransfected with Myc-TSC1 and Xpress-tagged
wt TSC2 or A2 TSC2 mutant were serum-starved and treated with or without 25 M U0126 for 30 min. Lysates were immunoprecipitated with
anti-Myc and blotted with Xpress and Myc antibodies, respectively.
(D) Erk-mediated disruption of the TSC1-TSC2 complex in vitro. Myc-TSC1 and Xpress-tagged wt TSC2 or A2 TSC2 mutant were coimmuno-
precipitated from serum-starved, U0126-treated (25 M, 30 min) 293T cells by anti-Myc and incubated in kinase buffer with or without
recombinant active Erk2 before being subjected to immunoblotting with Xpress and Myc antibodies.
(E) Disruption of the endogenous TSC1-TSC2 complex upon MAPK activation. 293 cells were serum-starved, stimulated with 1 g/ml PMA
for 40 min, or pretreated with 25 M U0126 for 30 min. Lysates were immunoprecipitated with anti-TSC2 and blotted with TSC1 and TSC2
antibodies, respectively.TOF/TOF MS/MS sequencing. Presence of unique frag-
ment ions confirmed the identity and the monophos-
phorylation state (characteristic loss of 98 amu) for thepeptide and allowed to narrow down the site of phos-
phorylation to either S660 or S664. In view of the se-
quence specificity of Erk (S/T-P directed), we con-
Cell
184Figure 5. Mutation of Erk Phosphorylation Sites Alters TSC2 Activity toward S6K
(A) Effect of U0126 (25 M) on PMA- (1 g/ml) induced S6K phosphorylation in 293 cells.
(B) Effect of U0126 (25 M) and wortmannin (100 nM) on Ras-induced S6K phosphorylation in 293 cells.
(C) Effect of wild-type and mutant TSC2 on MEK1-induced S6K phosphorylation. 293 cells were transfected with HA-S6K, HA-MEK1S218D/S222D,
Myc-TSC1 and Xpress-tagged wt TSC2 or TSC2 mutants: S664A/S540A (A2), or S664D/S540D (D2) and serum-starved.
(D) Effect of wild-type and mutant TSC2 on Ras-induced S6K phosphorylation. 293 cells were transfected with HA-S6K, HA-H-RasG12V, Myc-
TSC1 and Xpress-tagged wt TSC2 or TSC2 mutants (A2 or D2) and serum-starved.
(E) Effect of wild-type and mutant TSC2 on Rheb-induced S6K phosphorylation. 293 cells were transfected with HA-S6K, Myc-Rheb, Myc-
TSC1, and Xpress-tagged wt TSC2 or TSC2 mutants (A2 or D2) and serum-starved.
(F) Effect of wild-type and mutant TSC2 on endogenous S6K phosphorylation in Tsc2−/−p53−/− MEFs. Tsc2−/−p53−/− MEFs were transfected
with Xpress-tagged wt TSC2 or TSC2 mutants (A2 or D2) and serum-starved.
(G) Effect of RSK1 RNAi on basal and Ras- or MEK1-induced S6K phosphorylation. 293 cells were transfected with RSK1 siRNA or control
siRNA followed by HA-H-RasG12V or HA-MEK1S218D/S222D and HA-S6K and serum-starved.
Erk Regulates TSC2 and TSC-Related Tumorigenesis
185cluded that S664 is the directly phosphorylated residue
by Erk (Figure 3A). We performed the MS analysis
twice. S664 was characterized consistently as the di-
rect Erk phosphorylation site, whereas three additional
residues (S1097, S1449, S1452) were also identified,
but not consistently. In conclusion, while S664 is the
predominant site phosphorylated by Erk, additional Erk
phosphorylation sites may also exist. Their phosphory-
lation status may vary depending on the experimental
conditions or not be identified because of the sensitiv-
ity limit of the analysis.
To identify the primary in vivo TSC2 phosphorylation
sites, we expressed MEK1S218D/S222D in 293 cells to
specifically activate endogenous Erk (serum starva-
tion and wortmannin treatment were used to minimize
nonspecific phosphorylation, especially Akt-dependent
phosphorylation of TSC2). After immunoprecipitation,
SDS-PAGE, and Coomassie staining, the TSC2 bands
were subjected to MALDI-reTOF MS analysis. Peaks at
m/z = 1981.032 and 2061.010, corresponding to the
monoisotopic masses of protonated, tryptic peptides
encompassing S664 (i.e., TSGPLSPPTGPPGPAPAGP
AVR) in, respectively, the unphosphorylated and singly
phosphorylated forms, were observed. Subsequent
MALDI-TOF/TOF MS/MS analysis of the m/z peak at
2061 amu unequivocally confirmed the identity of the
peptide, and its monophosphorylation state (at S664;
data not shown). We therefore concluded that S664 is
the principal Erk phosphorylation site on TSC2 both
in vitro as well as in vivo.
To characterize further TSC2 residues possibly phos-
phorylated by Erk, we took advantage of a Scansite
database-scanning program (http://scansite.mit.edu;
Yaffe et al., 2001). We scanned the human TSC2 protein
for Erk phosphorylation motifs, which predicted six pu-
tative sites scanning at “medium stringency” (Figure
3B). A “high stringency” scan indicated two of the
above six sites as the most likely Erk phosphorylation
sites. In full agreement with the mass spectrometry
analysis, S664 scored in the top 0.001%. Additionally,
S540 scored in the top 0.147%. Both sites are con-
served among human, mouse, and rat (Figure 3B).
To determine the relevance of these sites in Erk-
dependent phosphorylation, we mutagenized S664 and
S540 to alanine, either singly or in combination, and
performed in vitro MAP kinase assay. Mutagenesis of
either S664 or S540 to alanine resulted in approximately
a 75% reduction in TSC2 phosphorylation, whereas
mutagenesis of both sites (TSC2S664A/S540A: A2 mutant)
almost abrogated TSC2 phosphorylation (Figure 3C),
demonstrating that S664 is a primary Erk phosphoryla-
tion site on TSC2 in vitro. S540 is also required for
proper in vitro phosphorylation, although we cannot ex-
clude the possibility that the mutagenesis of this site
(and of S664) may alter phosphorylation of other res-
idues.
We then further tested whether these two sites are also
Erk targets in vivo. Cotransfection of MEK1S218D/S222D
and TSC2 resulted in a pronounced induction of TSC2
phosphorylation, which was inhibited by U0126, while
the wortmannin effect was minimal (Figure 3D). Serine
to alanine substitution at S664 or double S664A/S540A
mutagenesis resulted in a marked reduction in TSC2
phosphorylation to a similar extent. In contrast, S540Asubstitution only moderately impaired TSC2 phosphor-
ylation (Figure 3D), corroborating the notion that in vivo
S664 is the most relevant residue for Erk-mediated
phosphorylation. Additionally, an Akt nonphosphoryla-
table mutant (TSC2S939A/T1462A) was phosphorylated by
Erk at levels comparable to the wild-type TSC2 (Figure
3D). Taken together, these results correlate well with the
Scansite prediction scores and the mass spectrometry
analysis.
Phosphorylation by Erk Leads to Dissociation
of the TSC1-TSC2 Complex
TSC2 exists in a complex with TSC1 in vivo (van Sleg-
tenhorst et al., 1998). The functional importance of the
complex formation has been supported by the fact that
a variety of disease-associated mutations weakens
TSC2 ability to bind TSC1 (Inoki et al., 2002). We hy-
pothesized that TSC2 phosphorylation upon MAPK ac-
tivation might have inhibitory effects on the TSC1-TSC2
complex, based on the fact that constitutively active
MAPKK results in oncogenic transformation (Mansour
et al., 1994), whereas TSC1 and TSC2 are tumor sup-
pressor genes. We therefore reasoned that a nonphos-
phorylatable TSC2 mutant (TSC2S664A/S540A; A2) would
be more active than wild-type TSC2, while a phospho-
mimetic mutant (TSC2S664D/S540D; D2) might be less
active. In fact, compared with wild-type TSC2,
TSC2S664A/S540A displayed a stronger association with
TSC1 at the steady state, whereas the interaction be-
tween TSC2S664D/S540D and TSC1 was weakened (Fig-
ure 4A). Furthermore, MAPK activation upon PMA treat-
ment resulted in abrogation in coimmunoprecipitation
of TSC2 by TSC1, which could be reverted by U0126.
In contrast, TSC1-TSC2S664A/S540A association was re-
sistant to PMA treatment (Figure 4B).
Surprisingly, the TSC2S664A/S540A mutant displayed a
stronger interaction with TSC1 than wild-type TSC2 un-
der serum-starved conditions (Figure 4B). One possi-
bility is that the alanine mutations might have caused a
conformational change on TSC2, allowing it to interact
more efficiently with TSC1. Alternatively, this observa-
tion can be attributed to basal levels of Erk activity. In
fact, it has been frequently documented that serum
starvation cannot completely eliminate the activity of
endogenous Erk1/2 in a variety of cultured cells, includ-
ing 293, 3T3, and MEF cells. To confirm this possibility,
we treated serum-starved cells with U0126, and strik-
ingly, inhibition of the basal activity of endogenous
Erk1/2 markedly enhanced the association between
TSC1 and wild-type TSC2. In contrast, the U0126 effect
on TSC1-TSC2S664A/S540A interaction was much smaller
(Figure 4C). As a result, upon abrogation of basal levels
of Erk activity, wild-type TSC2 binds TSC1 as strongly
as TSC2S664A/S540A, suggesting that the observed stronger
interaction between TSC1 and the TSC2S664A/S540A mu-
tant is Erk dependent (Figure 4C).
Consistent with the in vivo interaction (Figure 4B), we
also found that Erk phosphorylation of TSC2 could di-
rectly cause disruption of the TSC1-TSC2 complex, but
not the TSC1-TSC2S664A/S540A complex in vitro (Figure
4D), demonstrating that Erk-induced TSC1-TSC2 dis-
sociation depends mainly on phosphorylation mediated
by S664 and S540. Finally, we observed that inhibition
Cell
186Figure 6. Mutation of Erk Phosphorylation Sites Alters TSC2 Activity toward Cell Proliferation and Oncogenic Transformation
(A) Growth rate of Tsc2−/−p53−/− MEFs infected with wt TSC2 or TSC2 mutants.
(B) Soft agar transformation assay of Tsc2−/−p53−/− MEFs infected with wt TSC2 or TSC2 mutants.
(C) Growth rate of Tsc2+/+p53−/− MEFs infected with wt TSC2 or TSC2 mutants in combination with Ras.
(D) Soft agar transformation assay of Tsc2+/+p53−/− MEFs infected with wt TSC2 or TSC2 mutants in combination with Ras. A representative
experiment in triplicate, along with standard deviations, out of three with similar results is shown in (A)–(D).of basal Erk activity could promote the interaction of f
aendogenous TSC1-TSC2, whereas MAPK activation
upon PMA treatment led to disruption of the endoge- U
dnous complex, which was fully rescued by U0126 (Fig-
ure 4E). Thus, Erk-dependent phosphorylation antago- p
rnizes the formation of the TSC1-TSC2 complex.
(
SPhosphorylation by Erk Suppresses TSC2
Function toward S6K M
oOn the basis of the above observation that MAPK acti-
vation induces disruption of the TSC1-TSC2 complex, t
cit is conceivable that phosphorylation by Erk leads tounctional inactivation of TSC2 and, thereby, enhanced
ctivation of mTOR. We found that Erk inhibition by
0126 was sufficient to inhibit PMA-induced mTOR-
ependent p70S6K activation (as scored by T389 phos-
horylation, Burnett et al., 1998), indicating that Erk is
equired for mTOR activation upon PMA stimulation
Figure 5A). To date, oncogenic Ras (RasG12V)-induced
6K activation is believed to depend on PI3K, but not
APK, and occur through Akt inactivation of TSC2 (In-
ki et al., 2002; Shah et al., 2002). However, we found
hat either U0126 or wortmannin alone could signifi-
antly suppress S6K T389 phosphorylation in RasG12V-
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used in combination (Figure 5B), suggesting that
RasG12V-induced mTOR activation is both PI3K depen-
dent as well as MAPK dependent.
We next tested the effects of phosphorylation-defi-
cient and mimetic mutations on the ability of TSC2
to suppress mTOR-dependent S6K activation in the
presence of active MAPK. Indeed, we found that MAP
kinase activation induced by either MEK1S218D/S222D
or RasG12V enhanced S6K phosphorylation on T389,
and strikingly, S6K activation was only partially antago-
nized by wild-type TSC2 but nearly abolished by
TSC2S664A/S540A. In contrast, TSC2S664D/S540D had little
effect on MEK1- or Ras-induced S6K phosphorylation
(Figures 5C and 5D). On the other hand, wild-type TSC2
and TSC2S664A/S540A abrogated Rheb-induced S6K phos-
phorylation to the same extent, while TSC2S664D/S540D
was less effective (Figure 5E). Thus, in the absence of
MAPK activation, wild-type TSC2 and the Erk nonphos-
phorylatable TSC2 mutant are functionally equivalent,
whereas the TSC2 phosphomimetic mutant is function-
ally impaired both at the steady state and in the pres-
ence of activated Erk.
To substantiate the physiological relevance of our
findings, we then took advantage of Tsc2 null mouse
embryonic fibroblasts (MEFs) and tested the effects of
add-back of wild-type or TSC2 mutants on endogenous
S6K activity. As Tsc2 null MEFs undergo early-onset se-
nescence due to a dramatic p53-dependent induction
of p21 (Zhang et al., 2003a), Kwiatkowski and col-
leagues could only derive growing MEFs from com-
pound Tsc2−/−p53−/− mice. Compound Tsc2 and p53 in-
activation bypasses cellular senescence and lends a
marked growth advantage to Tsc2−/−p53−/− MEFs over
Tsc2+/+p53−/− MEFs (Zhang et al., 2003a). Importantly,
we found that in serum-starved Tsc2−/−p53−/− MEFs,
basal level of S6K phosphorylation on T389 and phos-
pho-Erk levels are constitutively very high (Figure 5F).
Furthermore, TSC2S664A/S540A add-back was much more
effective than wild-type TSC2 in inhibiting S6K phos-
phorylation on this mTOR-dependent site (Figure 5F).
Taken together, these data indicate that MAP kinase
activation leads to TSC2 inactivation through Erk-
dependent phosphorylation and that this in turn results
in mTOR-dependent S6K phosphorylation on T389 and
consequent activation.
Although the kinase substrates of Erk do not share
its phosphorylation motif, we next determined whether
the observed effects (e.g., mTOR activation) of Erk acti-
vation could be mediated by one of its numerous down-
stream targets. RSK1 is a potential candidate taking
into account a recent report whereby RSK1 phosphor-
ylates TSC2 at S1798 and possibly inactivates it (Roux
et al., 2004). Although the biological consequences of
this event were not studied, we wanted nevertheless to
assess whether RSK1 is required for Ras/Erk-mediated
mTOR activation. Transfection of RSK1 siRNA or the
dominant-negative mutant of RSK1 (RSK1K112R/K464R)
caused a significant reduction in RSK1 function (as
scored by BAD S112 phosphorylation; Bonni et al.,
1999) either with or without Erk activation (see Figures
S1A and S1B in the Supplemental Data available with
this article online), but it had no inhibitory effect on
either basal level or Ras/MEK1-induced S6K activation(Figures 5G and S2A–S2C). On the other hand, although
constitutively active RSK1 (myrRSK1) could enhance
TSC2 phosphorylation, expression of myrRSK1 alone
failed to activate S6K (Roux et al., 2004). Thus, RSK1
appears to be neither sufficient nor required for Erk-
mediated mTOR activation.
Phosphorylation by Erk Suppresses TSC2 Function
toward Cellular Proliferation and Transformation
To assess whether TSC2 phosphorylation by Erk would
affect its biological functions, we introduced wild-
type TSC2, TSC2S664A/S540A, or TSC2S664D/S540D into
Tsc2−/−p53−/− MEFs by retroviral infection and assayed
for cell proliferation and oncogenic transformation.
Add-back of wild-type TSC2 resulted in around 40%
inhibition compared with mock-infected cells, while
TSC2S664A/S540A infection resulted in approximately
40% inhibition compared with wild-type TSC2 (Figure
6A). Tsc2−/−p53−/− MEFs did form colonies when plated
in soft agar. Strikingly, wild-type TSC2 partially sup-
pressed while TSC2S664A/S540A abrogated their ability to
grow in an anchorage-independent manner. Surpris-
ingly, instead of inhibiting cellular transformation,
TSC2S664D/S540D enhanced colony formation (Figure
6B). Thus, TSC2 phosphorylation mediated by S664/
S540 antagonizes its tumor suppressive activity, while
the phosphomimetic TSC2S664D/S540D might act as a
protooncogenic gain-of-function mutant in certain con-
ditions.
To investigate whether TSC2 phosphorylation by Erk
is relevant to oncogenic Ras-induced growth and trans-
formation, we next expressed wild-type or mutant TSC2
in combination with RasG12V in Tsc2+/+p53−/− MEFs.
RasG12V markedly accelerated cell growth, which could
only be partly antagonized by wild-type TSC2. Ex-
pression of TSC2S664A/S540A completely abrogated the
growth-stimulating effect of Ras, while TSC2S664D/S540D
had little effect on Ras-induced growth (Figure 6C). Im-
mortalized Tsc2+/+p53−/− MEFs, when plated in soft
agar, displayed very low colony-forming activity, which
was markedly enhanced by RasG12V. TSC2S664A/S540A
expression almost completely antagonized Ras-induced
oncogenic transformation. In contrast, wild-type TSC2
and TSC2S664D/S540D only partially antagonized RasG12V
effects to a similar extent (approximately 50%, Figure
6D). The Erk nonphosphorylatable TSC2 mutant can
therefore bypass inactivation by Erk and effectively in-
hibit RasG12V-induced transformation to a nearly com-
plete extent.
Phosphorylation by Erk Suppresses TSC2 Tumor
Suppressive Function In Vivo
The key question that remained to be addressed was
whether Erk phosphorylation of TSC2 might serve as a
mechanism for TSC tumor development. In certain
TSC-associated tumors, including the most prevalent
and destructive TSC lesions—tumors in the central ner-
vous system (CNS)—TSC2 LOH is extremely rare (Hen-
ske et al., 1996; Niida et al., 2001). Instead, in these
brain lesions, immunoblotting and immunohistochem-
istry analysis revealed abnormally elevated Erk acti-
vation (Govindarajan et al., 2003; Han et al., 2004).
Moreover, TSC2ang1 cells derived from a cutaneous
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188Figure 7. A Nonphosphorylatable TSC2S664A/S540A Mutant, but Not Wild-Type TSC2, Antagonizes In Vivo Tumorigenesis in the TSC2ang1 Model
(A) Expression levels of TSC2, pS6K, and pErk in TSC2ang1 cells infected with empty vector, wt TSC2, or TSC2 mutants.
(B) Effect of U0126 (25 M) on S6K phosphorylation in TSC2ang1 cells infected with empty vector or wt TSC2.
(C) Colony formation in TSC2ang1 cells infected with empty vector, wt TSC2 or TSC2 mutants. Note the reduced number and size of colonies
from A2 infection (left panel; Scale bar, 10 mm). A representative experiment in triplicate, along with standard deviations, out of three with
similar results is shown in the right panel.
(D) Tumorigenesis in nude mice injected with TSC2ang1 cells infected with empty vector, wt TSC2, or TSC2 mutants. Photographs in the left
panel were taken six weeks after injection. A representative experiment along with standard deviations (n = 6), out of three with similar results
is shown in the right panel. Asterisks indicate statistically significant differences (*p < 0.01; **p < 0.0001), after t test comparing A2 against
wt. No significant differences were observed performing a similar statistical analysis when comparing tumor size from mock and wt TSC2-
infected cells.sarcoma of Tsc2+/− mice also displayed constitutive w
shigh levels of phospho-Erk but not phospho-Akt (Gov-
indarajan et al., 2003; Figure 7A and data not shown). b
cThese cells are genuinely representative of tumorigene-
sis occurring in the absence of TSC2 LOH, as the re- e
maining Tsc2 copy is intact and produces full-lengthild-type mRNA (data not shown). In addition, expres-
ion of the endogenous Tsc2 protein is readily detecta-
le (Figures 7A and 7B). Importantly, TSC2ang1 cells
an be used as a useful surrogate model of tumorigen-
sis in TSC as they are the only genetically defined TSCcell line known to form tumors in nude mice (Govindar-
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Tumorigenesis and Translational Control Me-
diated by Erk Signaling
(A) A biphasic model for tumor lesion devel-
opment in TSC.
(B) Mechanisms of TSC2 functional blockade
and mRNA translational control through con-
verging Ras-Erk and PI3K-Akt signaling cas-
cades.ajan et al., 2003). Furthermore, the in vivo tumorigene-
city of TSC2ang1 cells can be blocked by dominant-
negative MEK1, implying that Erk is involved in devel-
opment of TSC tumor lesions (Govindarajan et al.,
2003). We observed that these cells displayed high
levels of phospho-Erk and phospho-S6K (at T389; Fig-
ure 7A). Strikingly, introduction of wild-type TSC2 did not
inhibit S6K phosphorylation, whereas TSC2S664A/S540A
abolished it (Figure 7A), strongly suggesting that in tu-
mor cells constitutively expressing activated Erk, wild-
type TSC2 is inactivated while the Erk nonphosphory-
latable mutant retains activity. In fact, Erk inhibition
upon U0126 treatment could restore the ability of either
overexpressed or endogenous wild-type TSC2 to sup-
press S6K phosphorylation (Figure 7B).
We next examined whether expression of wild-type
or TSC2 mutants in TSC2ang1 cells would antagonize
tumorigenecity in vitro and in vivo. In soft agar colony-
forming assays, TSC2ang1 cells infected with empty
vector, wild-type TSC2, or TSC2S664D/S540D yielded
comparable numbers of colonies, whereas only cells
expressing TSC2S664A/S540A displayed a marked de-crease in colony number (approximately 60% reduc-
tion; Figure 7C). We then injected TSC2ang1 cells in-
fected with empty vector, wild-type TSC2, or TSC2
mutants subcutaneously into athymic nude mice. When
compared with mock-infected cells, expression of wild-
type TSC2 or TSC2S664D/S540D did not inhibit tumorige-
nicity in vivo, while a more than 70% reduction in tumor
size was observed from injection with TSC2S664A/S540A-
expressing cells (Figure 7D), demonstrating that in
TSC2+/− tumor cells in which Erk is constitutively acti-
vated, the tumor suppressive activity of TSC2 is abro-
gated both in vitro as well as in vivo, as a result of phos-
phorylation by Erk.
Discussion
The Molecular Mechanism of Erk-Mediated
TSC Tumorigenesis
TSC1 and TSC2 can function as classic tumor suppres-
sors, as evidenced by frequent occurrence of LOH in
TSC-associated renal tumors. However, analysis of
TSC-associated CNS lesions for allelic loss revealed
Cell
190LOH in only 4% of TSC brain lesions (Henske et al., i
n1996), while a more recent study reported no LOH in
TSC brain lesions (Niida et al., 2001), suggesting that e
Psome types of TSC tumors, including the very prevalent
CNS lesions, can result from mechanisms other than d
rLOH. Obviously, mutations in genes other than TSC1
or TSC2 could cooperate with their heterozygous loss.
TAlternatively, the haploid level of wild-type TSC protein
might be functionally “turned off.” Our data strongly c
psuggest that the second explanation may be true in a
large fraction of TSC2+/− tumors through Erk activation. t
HWe in fact demonstrate that wild-type TSC2 does not
inhibit tumorigenecity in vitro or in vivo; neither does it d
taffect phospho-S6K level in TSC2+/− tumor cells that
express high level of active Erk. In contrast, expression T
dof an Erk non-phosphorylatable TSC2 mutant leads to
complete abrogation of S6K phosphorylation and a re- i
amarkable reduction in tumorigenecity. Based on these
results, we propose a new biphasic model for tumori- T
tgenesis in TSC2 heterozygous organs in the absence
of LOH (Figure 8A): while germline mutation in one L
pTSC2 allele results in reduction in the level of wild-type
TSC2 protein, yet undetermined mechanisms lead to p
Tconstitutive activation of Erk at the somatic level. As a
consequence, the haploid TSC2 protein is phosphory- b
lated and fully inactivated, in turn leading to growth-
selective advantage and TSC tumor development. T
An intriguing corollary question is what advantage T
constitutive Erk activation would provide tumor cells W
heterozygous for TSC1. On one hand, Erk phosphoryla- g
tion of TSC2 would disrupt the TSC complex, thereby a
hindering the ability of the haploid TSC1 to form a func- T
tional unit with TSC2. Alternatively, TSC1 may also be t
a direct inhibitory phosphorylation target of Erk. In- d
deed, Erk could effectively phosphorylate TSC1 both R
in vitro and in vivo (data not shown). However, this c
event does not appear to contribute to the disruption
of the complex, as a TSC1-TSC2S664A/S540A complex is g
(fully resistant to MAPK activation (Figure 4B). In addi-
tion, we could not detect a physical interaction be- m
utween Erk and TSC1 (data not shown). Future studies
will help determine the role of TSC1 phosphorylation in a
aErk-mediated TSC tumorigenesis.
While Erk is constitutively activated in TSC tumors, L
fin renal cystadenomas from Tsc1+/− or Tsc2+/− mice and
in Tsc2−/− MEFs, Tsc1 or Tsc2 deficiency is found to t
tresult in impaired PI3K-Akt activation through negative
feedbacks such as PDGFR and IRS downregulation m
o(Zhang et al., 2003a; Harrington et al., 2004; Shah et al.,
2004). The fact that TSC2 deficiency triggers a negative c
efeedback that impairs PI3K-Akt activation may provide
an explanation for the reason why TSC lesions rarely i
tprogress to full-blown malignancy. These negative
feedbacks underscore, in turn, the critical relevance of t
sErk activation in tumor development in TSC patients.
Thus, although the physiological relevance of TSC2 t
ephosphorylation by Akt has been compellingly demon-
strated in Drosophila (Potter et al., 2002), whether TSC2 2
pinactivation by Akt plays an important role in TSC tu-
morigenesis remains to be determined. In this respect, v
nit is worth mentioning that so far PTEN has not been
found mutated in TSC tumor lesions (Han et al., 2004). m
pIn addition, although loss of the Tsc2 gene does accel-
erate tumorigenesis (e.g., prostate cancer progression) tn Pten+/− mice, the main tumor phenotype (renal carci-
oma) specifically observed in Tsc2+/− mice (Kobayashi
t al., 1999) is not enhanced by Pten loss (L.M. and
.P.P., unpublished data). Thus, the role of Akt-depen-
ent TSC2 phosphorylation in TSC pathogenesis war-
ants further investigation.
It should be noted that the phosphorylation profile of
SC2 in response to PMA stimulation appears to be
omplex (Ballif et al., 2005) and that Erk-mediated
hosphorylation of S664 might not account entirely for
he observed negative regulation of the TSC complex.
owever, our study demonstrates that S664 is the pre-
ominant Erk phosphorylation site on TSC2 both in vi-
ro and in vivo and that Erk-induced disruption of the
SC complex depends mainly on phosphorylation me-
iated by S664/S540. We also find that inhibition of Erk
s sufficient to revert PMA induced TSC1-TSC2 dissoci-
tion, as well as to inhibit PMA- or Ras-induced S6K
389 phosphorylation. In human TSC patients, it is Erk
hat is aberrantly activated in tumors lacking TSC2
OH. Therefore, the contribution of Erk-independent
hosphorylation sites or other Erk-dependent phos-
horylation sites to the observed negative regulation of
SC2 in response to PMA or activated Erk appears to
e minor.
he Molecular Mechanism of Erk-Dependent mRNA
ranslational Control
e show that Ras-induced cell proliferation and onco-
enic transformation depends, at least in part, on its
bility to trigger the Erk-dependent phosphorylation of
SC2 and that through this mechanism Ras-Erk activa-
ion can lead to activation of S6K through the mTOR-
ependent site T389. These results in turn imply that
as-MAPK signaling may contribute to translational
ontrol through the TSC1/2-mTOR pathway.
Protein synthesis plays an essential role in cell
rowth, differentiation, and oncogenic transformation
Clemens and Bommer, 1999), as well as in long-term
emory storage (Davis and Squire, 1984). It is well doc-
mented that mTOR can be phosphorylated at S2448
nd activated through Akt-dependent phosphorylation
nd inactivation of the TSC complex (Inoki et al., 2002;
i et al., 2004). The PI3K-Akt-mTOR cascade is there-
ore considered a major regulatory axis for mRNA
ranslation control. In contrast, the established role of
he Ras-Erk pathway is to regulate transcription (Treis-
an, 1996), while the role of this pathway in modulation
f mRNA translation has remained to date elusive. Re-
ent studies on long-term memory underscored, how-
ver, the physiological importance of MAPK signaling
n translational control (Kelleher et al., 2004). Until now,
he only mechanistic link between MAPK signaling and
he mRNA translation machinery is provided by the ob-
ervation that the recently cloned MAPK-activated pro-
ein kinase, Mnk1 or Mnk2, can directly phosphorylate
IF4E at S209 (Pyronnet et al., 1999; Scheper et al.,
001; Waskiewicz et al., 1999). However, S209 phos-
horylation of eIF4E is not essential for growth or de-
elopment, since the Mnk1−/−Mnk2−/− mice developed
ormally, and in MEFs derived from these double null
utants, neither cap-dependent translation nor total
rotein synthesis is affected despite complete abroga-
ion of eIF4E S209 phosphorylation (Ueda et al., 2004).
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through which MAPK can modulate mRNA translation,
which, when deregulated, can lead to disease and tu-
morigenesis (Figure 8B): mitogenic stimuli or oncogenic
Ras activates the Raf-MEK1/2-Erk1/2 signaling cas-
cade leading to phosphorylation of TSC2 by Erk1/2 and
the consequent functional inactivation of the TSC1-
TSC2 complex. This signaling axis can therefore coop-
erate with the PI3K/Akt axis in inactivating TSC2
through phosphorylation on distinct residues, thus
leading to mTOR activation, S6K activation, 4E-BP1 in-
activation, and ultimately, activation of mRNA trans-
lation.
Experimental Procedures
Plasmids, Antibodies, and Chemicals
Human Xpress-TSC2 and Myc-TSC1 were generously provided by
M. Nellist. FLAG-TSC2, HA-S6K, and HA-RSK1K112R/K464R were
from J. Blenis. HA-Erk2 and Myc-Rheb were from K. Guan. HA-
RasG12V was purchased from Guthrie. HA-MEK1S218D/S222D was
purchased from Upstate. All mutant constructs of TSC2 were gen-
erated using a QuikChange site-directed mutagenesis kit (Strata-
gene). The antibodies used in this study were anti-FLAG (Sigma);
anti-phosphoserine/threonine (BD Biosciences); anti-Xpress (Invit-
rogen); anti-HA and anti-Myc (Covance); anti-pErk, anti-Erk, anti-
pAkt, anti-Akt, anti-pS6K, anti-S6K, anti-pBAD and anti-BAD (Cell
Signaling Technology); anti-FAK and anti-RSK1 (Upstate Biotech-
nology); anti-TSC2 (Santa Cruz); and anti-TSC1 (Zymed). U0126
and wortmannin were from Calbiochem. PMA, polybrene, and pu-
romycin were from Sigma. EGF and hygromycin were from Upstate
and Invitrogen, respectively.
Cell Culture, Transfections, and Infections
All cells were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM
glutamine, and 100 U/ml penicillin and streptomycin (GIBCO).
HEK293, HEK293T, and TSC2ang1 cell lines were from ATCC.
Tsc2−/−p53−/− and Tsc2+/+p53−/− MEFs were generous gifts from D.
Kwiatkowski. Transfections were performed using Lipofectam-
ine2000 reagent (Invitrogen) according to manufacturer’s instruc-
tions. In brief, 4 hr after transfection, cells were recovered in full
serum for 40 hr or in full serum for 24 hr and then serum-starved
for 16 hr as indicated. Wild-type or mutant TSC2 were subcloned
into the pBabe-puromycin retroviral vector. RasV12 cDNA was sub-
cloned into the pBabe-hygromycin vector. The Phoenix packaging
cells were transfected with the empty pBabe vector or the vector
containing TSC2 or RasV12 cDNA using Lipofectamine2000 re-
agent. Seventy-two hours after transfection, the retroviral superna-
tants were collected and filtered through a 0.45 m filter and used
for infections: 3 ml of freshly made retroviral supernatants contain-
ing 4 g/ml polybrene were added to exponentially growing cells
for each 10 cm diameter plate culture. After 3 hr, 7 ml fresh medium
was added. Normally, three rounds of infections were performed at
6 hr intervals. Cells were selected with appropriate antibiotics 72
hr after infection.
RNA Interference
SMARTpool RSK1 (Dharmacon) represents four pooled SMART se-
lected siRNA duplexes that target RSK1. HEK293 cells were trans-
fected with SMARTpool RSK1 or nonspecific control pool using
Oligofectamine reagent (Invitrogen) according to manufacturer’s in-
structions. In brief, 200 nM final concentration of siRNA was used
to transfect cells at 40%–50% confluency. Four hours after trans-
fection, cells were recovered in full serum. Twenty-four hours later,
cells were transfected with indicated plasmids using Lipofectam-
ine2000 reagent and serum-starved 16 hr before harvest. Cells
were harvested 72 hr after siRNA transfection.
Immunoblotting and Immunoprecipitation
Cells were harvested in RIPA lysis buffer (150 mM NaCl, 10 mM Tris
[pH 7.5], 1% NP40, 1% deoxycholate, 0.1% SDS, protease inhibitorcocktail [Roche], phosphatase inhibitor cocktail [Sigma]) or in case
of coimmunoprecipitation, in E1A lysis buffer (250 mM NaCl, 50 mM
HEPES [pH 7.5], 0.1% NP40, 5 mM EDTA, protease inhibitor cock-
tail [Roche], phosphatase inhibitor cocktail [Sigma]). For immuno-
precipitation, lysates were precleared with IgG and then incubated
with the precipitating antibody overnight, followed by 1 hr incuba-
tion with protein A/G beads (Santa Cruz). Immune complexes were
then washed three times in lysis buffer and boiled in gel loading
buffer. Proteins from total cell lysates or immunoprecipitates were
resolved by sodium dodecyl sulfate (SDS)-poly-acrylamide gel ele-
trophoresis (PAGE), transferred to nitrocellulose membrane,
blocked in 5% nonfat milk or BSA, and blotted with the appropri-
ate antibody.
CIP Treatment
The protein A/G beads used for immunoprecipitating endogenous
TSC2 were washed three times in RIPA buffer then washed twice
in CIP buffer (100 mM NaCl, 50 mM Tris [pH 7.9], 10 mM MgCl2, 1
mM dithiothreitol), followed by incubation with 1 l of 10 U/l CIP
(New England Biolabs) in 50 l CIP buffer for 1 hr at 37°C. Reac-
tions were stopped by washing twice in CIP buffer and boiling in
gel loading buffer.
In Vitro MAP Kinase Assay
Xpress-tagged wild-type TSC2 or S664A, S540A, and S664A/S540A
mutants were immunoprecipitated from serum-starved 293T cells
by Xpress antibody. Immune complexes were washed three times
in lysis buffer then washed twice in kinase buffer (25 mM HEPES,
10 mM magnesium acetate, 50 M ATP [pH 7.5]) and incubated
with 0.1 g purified activated Erk2 (Stratagene) and 2 Ci [γ-32P]-
ATP in 40 l kinase buffer for 30 min at 30°C. Reactions were
stopped by washing twice in kinase buffer and boiling in gel load-
ing buffer. Proteins were resolved by 5% SDS-PAGE and transfer-
red to the nitrocellulose membrane, and 32P incorporation was de-
tected by autoradiography.
In Vitro Phosphorylation Site Mapping (Mass Spectrometry)
Gel-resolved proteins from in vitro phosphorylation reactions were
digested with trypsin, batch purified on a reversed-phase (RP)
micro-tip, and an aliquot was analyzed by matrix-assisted laser de-
sorption/ionization reflectron time-of-flight (MALDI-reTOF) mass
spectrometry (MS; UltraFlex TOF/TOF; BRUKER Daltonics; Bre-
men, Germany) for peptide mass fingerprinting, as described (Seb-
astiaan Winkler et al., 2002). This served to confirm the identity of
the proteins and to locate possible differences between the tryptic
peptide maps of the phosphorylated and unphosphorylated forms.
The remainder of the RP-eluted digest mixtures was then subjected
to immobilized gallium (III) affinity chromatography for selective
capture of phosphopeptides, followed by elution with phosphate
buffer, desalting over an RP tip, and a second round of MALDI-
reTOF MS (Posewitz and Tempst, 1999). Peak m/z values were
matched to the protein sequence, allowing for the likely presence
of one or more phosphate groups. Mass spectrometric sequencing
of the putative phosphopeptides was then carried by MALDI-TOF/
TOF MS/MS analysis using the UltraFlex instrument in “LIFT”
mode. Fragment ion spectra were inspected for a$, b$, and y$ ions
to compare with the computer-generated fragment ion series of the
predicted tryptic peptides to locate the exact position of phos-
phoamino acids.
Cell Growth Rate and Soft Agar Assay
Retrovirally infected cells were selected in 2 g/ml puromycin (plus
75 g/ml hygromycin in case of double infection) for 3 days. Cell
growth rate was determined as published (Zhang et al., 2003a).
Briefly, 2 × 104 cells were plated in each well of a six-well plate.
From the next day, cells were trypsinized and counted using a hem-
atocytometer every day until confluency. For soft agar transforma-
tion assay, 5 × 104 cells were placed in 1.5 ml DMEM with 10%
FBS and 0.3% agarose and overlaid onto 3 ml DMEM with 10%
FBS and 0.6% agarose in each well of a six-well plate. After 2–3
weeks, colonies larger than 3 mm in diameter were counted.
Cell
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nRetrovirally infected TSC2ang1 cells were selected in 2 g/ml puro-
mycin for three days. 1 × 106 cells were resuspended in DMEM and G
injected subcutaneously into the right flank of 6-week-old athymic S
nude mice (NCRNU-M, Taconic Farms Inc.). The remaining cells (
were used for soft agar assay and immunoblotting against TSC2, s
phospho-S6K, S6K, phospho-Erk, and Erk. Tumor size was mea-
G
sured weekly using a caliper, and tumor volume was determined
R
by using the standard formula: L × W2 × 0.52, where L is the longest
Gdiameter and W is the shortest diameter.
o
P
GSupplemental Data
GSupplemental Data include two figures and Supplemental Experi-
smental Procedures and can be found with this article online http://
awww.cell.com/cgi/content/full/121/2/179/DC1/.
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